Back to top
more

bluebird bio (BLUE)

(Delayed Data from NSDQ)

$0.92 USD

0.92
8,159,743

-0.05 (-4.91%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $0.94 +0.02 (1.85%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Is a Beat in Store for Bristol-Myers (BMY) in Q2 Earnings?

by Zacks Equity Research

Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports second-quarter 2021 results.

Bristol-Myers (BMY) Gains 7.6% YTD: What to Expect in 2H

by Zacks Equity Research

Bristol-Myers (BMY) maintains momentum on new drug approvals despite some key established drugs facing challenges.

Bristol Myers (BMY) Gets Positive CHMP Opinion for Abecma

by Zacks Equity Research

Bristol Myers (BMY) obtains positive CHMP opinion for cell immunotherapy, Abecma, for multiple myeloma and Opdivo for the indication of gastroesophageal junction cancer.

Bristol Myers' (BMY) Onureg Gets European Commission Approval

by Zacks Equity Research

Bristol Myers (BMY) wins approval for acute myeloid leukemia drug, Onureg, in the European Union.

Bristol-Myers (BMY) Partners Eisai for Antibody Drug Conjugate

by Zacks Equity Research

Bristol-Myers (BMY) teams up with Eisai to co develop MORAb-202, an antibody drug conjugate (ADC).

Bristol Myers (BMY) Announces Data on CAR T Cell Therapy Breyanzi

by Zacks Equity Research

Bristol Myers (BMY) announces positive data on CAR T cell therapy, Breyanzi, in the second-line setting for patients with relapsed or refractory large B-cell lymphoma.

Biotech Stock Roundup: BIIB's Drug Approval, ALXN Drug Label Expansion & More

by Zacks Equity Research

The biotech sector was in focus last week with regulatory updates from Biogen (BIIB) and bluebird (BLUE), among others.

bluebird (BLUE) Resumes SCD & TDT Studies as FDA Lifts Hold

by Zacks Equity Research

The FDA lifts the clinical hold on bluebird's (BLUE) studies on LentiGlobin for sickle cell disease and betibeglogene autotemcel for transfusion-dependent thalassemia. Shares rise.

Why Is Bluebird (BLUE) Up 3.5% Since Last Earnings Report?

by Zacks Equity Research

Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Bristol-Myers (BMY) Teams Up With Agenus for Antibody Program

by Zacks Equity Research

Bristol-Myers (BMY) obtains exclusive license for Agenus' antibody program, AGEN1777, for an upfront payment of $200 million and up to $1.36 billion in milestone payments.

Bristol Myers (BMY) Announces New Data on Cardiovascular Candidate

by Zacks Equity Research

Bristol Myers (BMY) announces new positive data on mavacamten from a late-stage study at the American College of Cardiology's 70th Annual Scientific Session.

bluebird (BLUE) Q1 Loss Wider Than Expected, Revenues Beat

by Zacks Equity Research

bluebird (BLUE) reports a wider-than-expected loss for the first quarter of 2021 while revenues beat estimates.

Bluebird Bio (BLUE) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Bluebird (BLUE) delivered earnings and revenue surprises of -0.66% and 19.44%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Viatris (VTRS) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Investors will look forward to regular top and bottom-line numbers and updates on the merger synergies when Viatris (VTRS) reports Q1 results.

Bluebird Bio (BLUE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

by Zacks Equity Research

Bluebird (BLUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is a Beat in the Cards for Twist (TWS) This Earnings Season?

by Zacks Equity Research

Investors will focus on the top-line and bottom-line numbers when Twist (TWST) reports fiscal second-quarter 2021 results.

Bristol-Myers (BMY) Misses on Q1 Earnings, Opdivo Sales Decline

by Zacks Equity Research

Bristol-Myers (BMY) misses earnings and sales estimates in the first quarter on weak Opdivo sales.

What's in the Cards for Bristol-Myers (BMY) Q1 Earnings?

by Zacks Equity Research

Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports first-quarter 2021 results.

Anthem's (ANTM) Q1 Earnings Beat Estimates, Increase Y/Y

by Zacks Equity Research

Anthem's (ANTM) Q1 earnings gain from better revenues and strong Medicaid and Medicare businesses.

Tenet Healthcare's (THC) Q1 Earnings Surpass, Improve Y/Y

by Zacks Equity Research

Tenet Healthcare's (THC) first-quarter earnings gain from better revenues and impressive contributions from its Hospital operations and Ambulatory segments.

Here's How Investors Can Find Strong Medical Stocks with the Zacks ESP Screener

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

What's in Store for HCA Healthcare's (HCA) Q1 Earnings?

by Zacks Equity Research

HCA Healthcare's (HCA) first-quarter earnings are likely to have witnessed better patient volumes and improved revenues.

Biotech Stock Roundup: BLUE/BMY's CAR T Therapy Nod, KLDO's COVID-19 Study News & More

by Zacks Equity Research

The biotech sector gains prominence with new product approvals from bluebird (BLUE)/Bristol Myers Squibb (BMY) and other coronavirus updates.

bluebird (BLUE), Bristol Myers CAR T Cell Therapy Gets FDA Nod

by Zacks Equity Research

bluebird (BLUE) and partner Bristol Myers clinch an FDA approval for their chimeric antigen receptor T cell immunotherapy Abecma to address relapsed or refractory multiple myeloma.

Bluebird (BLUE) Up 9.1% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.